Welcome to our dedicated page for Scholar Rock Holding SEC filings (Ticker: SRRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Scholar Rock Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Scholar Rock Holding's regulatory disclosures and financial reporting.
Mo Qatanani, Chief Scientific Officer of Scholar Rock Holding Corp (SRRK), reported an insider sale on a Form 4. On 09/22/2025 the reporting person sold 3,353 shares of Scholar Rock common stock at a weighted average price of $30.6729 under a Rule 10b5-1 trading plan adopted March 31, 2025. After the sale the reporting person beneficially owns 108,964 shares represented by RSUs. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person and filed on 09/24/2025. The filing discloses the sale occurred in multiple transactions at prices ranging from $30.33 to $30.85, and the weighted average reflects those executions.
Scholar Rock Holding Corporation reported that the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for its Biologics License Application for apitegromab, a treatment candidate for spinal muscular atrophy (SMA). The company disclosed that it announced the CRL in a press release dated September 23, 2025, which is furnished as an exhibit. A CRL means the FDA has completed its review of the application and, instead of approving it in its current form, has provided feedback that must be addressed before approval can be granted.
Scholar Rock Holding Corp (SRRK) filed a Form 144 disclosing a proposed sale of 3,353 common shares through J.P. Morgan Securities LLC on 09/22/2025 with an aggregate market value of $102,846. The shares were acquired on 09/15/2025 as a restricted stock award from the issuer and were paid for on the acquisition date. The filing reports 67,122,987 shares outstanding for the class. The notice also lists a prior sale on 07/08/2025 where Mohammed Qatanani sold 24,066 shares for gross proceeds of $828,897. The filer affirms they are not aware of undisclosed material adverse information and references Rule 10b5-1 trading plan disclosure language.
Katie Peng, a director of Scholar Rock Holding Corp (SRRK), reported sales of common stock on 09/16/2025 under a Rule 10b5-1 plan adopted 11/20/2024 to cover tax obligations from RSU vesting. The filing shows two sale events: 930 shares sold at a weighted average price of $32.4761 and 76 shares sold at a weighted average price of $33.1963, executed in multiple transactions at prices ranging $31.85–$33.73. After these sales Ms. Peng beneficially owns 33,990 shares following the first reported sale and 33,914 shares following the second, held directly and including unvested RSUs. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Insider transaction summary for Scholar Rock Holding Corp (SRRK): The reporting person, Mo Qatanani, Chief Scientific Officer, completed a sell-to-cover transaction on 09/16/2025 disposing of 3,178 shares of common stock at $33.52 per share to satisfy tax withholding arising from RSU vesting. After the transaction, the reporting person beneficially owns 112,317 shares, comprised of 3,353 issued shares and 108,964 unvested restricted stock units that vest over four years from grant dates in 2021 and 2022. The sell-to-cover was executed by a brokerage firm as required under the issuer's equity plan and was not a discretionary trade by the reporting person.
Form 144 filed for Scholar Rock Holding Corp (SRRK) reporting a proposed sale of 1,006 shares of common stock through J.P. Morgan Securities LLC on 09/16/2025. The filing shows an aggregate market value of $32,726 for the shares, with 96,127,265 shares outstanding. The securities to be sold were acquired as restricted stock units: 261 shares on 08/15/2025 and 745 shares on 09/15/2025, with payment indicated as NA. No sales by the reporting person in the prior three months are reported. The filing includes the required representation that the seller does not possess undisclosed material adverse information.
Caryn Parlavecchio, Chief Human Resources Officer of Scholar Rock Holding Corp (SRRK), reported a non-discretionary sale of common stock on 08/18/2025 to cover tax withholding for vested restricted stock units (RSUs). The Form 4 shows 2,178 shares were sold at $31.1663 per share as a mandatory "sell-to-cover" tied to RSUs that vested on 08/15/2025. After the transaction the reporting person beneficially owned 155,464 shares in total, comprising 66,222 common shares and 89,242 RSUs. The filing was signed by an attorney-in-fact on 08/19/2025.